Show/hide main menu

News

News Highlights

Anti-inflammatory drugs' effect on depression

Posted on 14/01/2015
Anti-inflammatory drugs and depression

Scientists from King’s are part of a new consortium looking at whether existing anti-inflammatory drugs could be repurposed to provide fresh treatments for Alzheimer’s disease and depression.  It will be the largest study ever investigating inflammation in the brain.

Previous studies have indicated that the immune system ‘talks to the brain’ in some way and that inflammation in the body can cause depression.  The consortium,  led by Cambridge University and comprising seven UK institutions, has received £5 million funding from the Wellcome Trust to take this research further. Professors Carmine Pariante and Federico Turkheimer from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) are leading the project for King’s and will be responsible for the coordination and delivery of the PET component of the study. The imaging work done at King’s will determine whether depressed patients have increased inflammation in the brain, and a further experimental study will assess the possibility of inducing depression by increasing inflammation levels.

Professor Pariante said: “We have known for the last few years that patients with depression have changes measurable in the blood that indicate activation of the inflammatory system - a biological response which is predominantly directed to fight infection but also has an important role in regulating behaviour. The time is now ripe to further consolidate this line of research in order to discover how increased inflammation causes depression, and - mostly importantly - whether tackling inflammation can offer a cure to the many depressed patients that do not get better using current antidepressants.”

The study will be carried out in two stages with the first aiming to shed light on the precise relationship between immune-related markers in the blood and brain function. If the first stage is successful, the second stage will be ‘proof-of-concept’ medical trials on patients with appropriate immunological profiles. The facilities and expertise at King’s and the IoPPN will play an important part in the research at each stage.

“King’s has a really prominent role in this large research programme on depression, co-leading both the clinical and preclinical research streams and being responsible for coordinating one of the most innovative aspects of the study: the visualisation of inflammation in the brain of depressed patients,” said Professor Pariante. “Most studies until now have focussed on measuring inflammation in the blood, but this will be the largest study ever investigating inflammation in the brain and will use a variety of techniques, including PET and MRI, both in depressed patients and in experimental models of depression.”

For further information contact Tom Bragg, Press Officer at IoPPN, King’s College London, on +44(0)2078485377 or email ioppn-pr@kcl.ac.uk

Rss Feed Atom Feed

News Highlights:

News Highlights...RSS FeedAtom Feed

Acetylcholine's role in cognitive flexibility

Acetylcholine's role in cognitive flexibility

Description
The neurotransmitter acetylcholine plays a key role in cognitive flexibility, a finding that has implications for treatments to restore brain function, according to research from the IoPPN, recently published in the Journal of Neuroscience.
Psychopathic offenders' response to punishment

Psychopathic offenders' response to punishment

Description
Adults with psychopathic personality disorder process information related to punishment and reward differently due to functional differences in their brains, according to a new study from researchers at the IoPPN, published in Lancet Psychiatry.
Video-based therapy for babies to prevent autism

Video-based therapy for babies to prevent autism

Description
A new form of video-based therapy has been tested to treat infants at familial risk for autism as early as seven months by researchers at the IoPPN, University of Manchester, and Birkbeck, and recently published in Lancet Psychiatry.

Share this story:

 

Follow Us

@kingscollegelon

Live Twitter feed...

@kingscollegelon
Join the conversation
Sitemap Site help Terms and conditions Privacy policy Accessibility Modern slavery statement Contact us

© 2017 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454